LRATD2 as A Potential Drug Target for Alzheimer's, Parkinson's and Chronic Pain

Target Name: LRATD2

NCBI ID: G157638

LRATD2

LRATD2 as A Potential Drug Target for Alzheimer's, Parkinson's and Chronic Pain

LRATD2 (NSE2) is a protein that is expressed in the nervous system and has been identified as a potential drug target for the treatment of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and chronic pain. LRATD2 is a scaffold protein that is involved in the formation of the dendrites, which are the branching extensions of neurons that receive signals from other neurons.

The study of LRATD2 and its potential as a drug target began in 2012, when a team of researchers led by Dr. Yasmina Boudjemaa at the University of Montreal found that LRATD2 was overexpressed in the brains of people with Alzheimer's disease. The researchers then used RNA interference technology to reduce the amount of LRATD2 in the brains and found that this reduced the formation of beta-amyloid plaques, a hallmark of Alzheimer's disease.

Following this study, further research was conducted to investigate the potential benefits of targeting LRATD2. Studies have shown that LRATD2 is involved in the formation of other hallmark proteins of Alzheimer's disease, including tau and beta-proteasome. These proteins are thought to play a role in the destruction of nerve cells in the brain, which is believed to contribute to the symptoms of Alzheimer's disease.

In addition to its involvement in the formation of Alzheimer's disease hallmark proteins, LRATD2 has also been shown to play a role in the regulation of pain. Studies have shown that LRATD2 is involved in the production of pain signals in the brain and that targeting LRATD2 with drugs can provide relief from chronic pain.

The potential drug target for LRATD2 is currently being investigated in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and chronic pain. The use of RNA interference technology to reduce the amount of LRATD2 in the brain has been shown to be effective in animal models of these disorders.

While the use of LRATD2 as a drug target is still in its early stages, the potential benefits of targeting this protein make it an attractive area of research. Further studies are needed to fully understand the role of LRATD2 in the development and progression of these disorders, as well as to determine the safety and effectiveness of targeting LRATD2 using RNA interference technology.

Overall, LRATD2 is a protein that has the potential to be a drug target for the treatment of Alzheimer's disease, Parkinson's disease, and chronic pain. Further research is needed to fully understand its role in these disorders and to develop safe and effective treatments.

Protein Name: LRAT Domain Containing 2

The "LRATD2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LRATD2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets